The Evidence of Glioblastoma Heterogeneity

Abstract

Cancers are composed of heterogeneous combinations of cells that exhibit distinct phenotypic characteristics and proliferative potentials. Because most cancers have a clonal origin, cancer stem cells (CSCs) must generate phenotypically diverse progenies including mature CSCs that can self-renew indefinitely and differentiated cancer cells that possess limited proliferative potential. However, no convincing evidence exists to suggest that only single CSCs are representative of patients' tumors. To investigate the CSCs' diversity, we established 4 subclones from a glioblastoma patient. These subclones were subsequently propagated and analyzed. The morphology, the self-renewal and proliferative capacities of the subclones differed. Fluorescence-activated cell sorting and cDNA-microarray analyses revealed that each subclone was composed of distinct populations of cells. Moreover, the sensitivities of the subclones to an inhibitor of epidermal growth factor receptor were dissimilar. In a mouse model featuring xenografts of the subclones, the progression and invasion of tumors and animal survival were also different. Here, we present clear evidence that a brain tumor contains heterogeneous subclones that exhibit dissimilar morphologies and self-renewal and proliferative capacities. Our results suggest that single cell-derived subclones from a patient can produce phenotypically heterogeneous self-renewing progenies in both in vitro and in vivo settings.

Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

“…At present, the alkylating drug TMZ is used as the first-line treatment for primary GBM (1). The heterogeneous character of GBM cells complicates the evaluation of interference of TMZ with various cellular signaling pathways (24). However, the primary influences of TMZ on cellular signaling pathways require elucidation to analyze adverse side effects as well as potential accompanying therapeutic approaches.…”

Perspectives and Challenges in Molecular-Based Diagnostics and Personalized Treatment for Recurrent High-Grade Gliomas

“…Moreover, gene expression signatures characteristic of distinct glioblastoma subtypes were found to be more profound in GSCs than in their tumours of origin, likely reflecting the impact of intratumoural heterogeneity in tumour samples [62]. The reason for these discrepant findings remains unclear but may in part be attributable to heterogeneity of GSC types and intratumoural regional variations in the composition of GSC types [63]. By using single cell cloning approach Soeda and co-authors have recently shown that different types of molecularly distinct GSCs varying in the degree of tumorigenicity and drug sensitivities co-exist within the same tumour [63].…”

Assessment of Anti-Proliferative Activities of Selected Medicinal Plant Extracts Used for Management of Diseases around Lake Victoria Basin

“…The reason for these discrepant findings remains unclear but may in part be attributable to heterogeneity of GSC types and intratumoural regional variations in the composition of GSC types [63]. By using single cell cloning approach Soeda and co-authors have recently shown that different types of molecularly distinct GSCs varying in the degree of tumorigenicity and drug sensitivities co-exist within the same tumour [63]. The emerging consensus is that intratumoural heterogeneity notorious in GBs is primarily contributed by GSCs owing to their inherent plasticity and capability to interconvert between different states [48].…”